Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
Häkkinen, Katja; Kiander, Wilma; Kidron, Heidi; Lähteenvuo, Markku; Urpa, Lea; Lintunen, Jonne; Vellonen, Kati Sisko; Auriola, Seppo; Holm, Minna; Lahdensuo, Kaisla; Kampman, Olli; Isometsä, Erkki; Kieseppä, Tuula; Lönnqvist, Jouko; Suvisaari, Jaana; Hietala, Jarmo; Tiihonen, Jari; Palotie, Aarno; Ahola-Olli, Ari V.; Niemi, Mikko (2023)
Lataukset:
Häkkinen, Katja
Kiander, Wilma
Kidron, Heidi
Lähteenvuo, Markku
Urpa, Lea
Lintunen, Jonne
Vellonen, Kati Sisko
Auriola, Seppo
Holm, Minna
Lahdensuo, Kaisla
Kampman, Olli
Isometsä, Erkki
Kieseppä, Tuula
Lönnqvist, Jouko
Suvisaari, Jaana
Hietala, Jarmo
Tiihonen, Jari
Palotie, Aarno
Ahola-Olli, Ari V.
Niemi, Mikko
2023
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202303293322
https://urn.fi/URN:NBN:fi:tuni-202303293322
Kuvaus
Peer reviewed
Tiivistelmä
Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated with altered transporter function that can predispose patients to adverse drug effects with statin treatment. We explored the effect of six rare SLCO1B1 single nucleotide variants (SNVs) occurring in Finnish individuals with a psychotic disorder on expression and functionality of the OATP1B1 protein. The SUPER-Finland study has performed exome sequencing on 9381 individuals with at least one psychotic episode during their lifetime. SLCO1B1 SNVs were annotated with PHRED-scaled combined annotation-dependent (CADD) scores and the Ensembl variant effect predictor. In vitro functionality studies were conducted for the SNVs with a PHRED-scaled CADD score of >10 and predicted to be missense. To estimate possible changes in transport activity caused by the variants, transport of 2′,7′-dichlorofluorescein (DCF) in OATP1B1-expressing HEK293 cells was measured. According to the findings, additional tests with rosuvastatin and estrone sulfate were conducted. The amount of OATP1B1 in crude membrane fractions was quantified using a liquid chromatography tandem mass spectrometry-based quantitative targeted absolute proteomics analysis. Six rare missense variants of SLCO1B1 were identified in the study population, located in transmembrane helix 3: c.317T>C (p.106I>T), intracellular loop 2: c.629G>T (p.210G>V), c.633A>G (p.211I>M), c.639T>A (p.213N>L), transmembrane helix 6: 820A>G (p.274I>V), and the C-terminal end: 2005A>C (p.669N>H). Of these variants, SLCO1B1 c.629G>T (p.210G>V) resulted in the loss of in vitro function, abolishing the uptake of DCF, estrone sulfate, and rosuvastatin and reducing the membrane protein expression to 31% of reference OATP1B1. Of the six rare missense variants, SLCO1B1 c.629G>T (p.210G>V) causes a loss of function of OATP1B1 transport in vitro and severely decreases membrane protein abundance. Carriers of SLCO1B1 c.629G>T might be susceptible to altered pharmacokinetics of OATP1B1 substrate drugs and might have increased likelihood of adverse drug effects such as statin-associated musculoskeletal symptoms.
Kokoelmat
- TUNICRIS-julkaisut [18592]